Advertisement

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Collyar: What's In It for Patients?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement

Aug

11

Today In Oncology

Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care

AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer

First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer

NIH-Funded International Research Yields Patient-Derived Tumor Compendium

Stanford Appoints New Leader to Expand Impact in Early Drug Development

Advertisement

© 2026 HSP News Service, L.L.C.